COSTI, Maria Paola
 Distribuzione geografica
Continente #
NA - Nord America 23.557
EU - Europa 14.825
AS - Asia 2.422
SA - Sud America 68
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 26
OC - Oceania 21
Totale 40.956
Nazione #
US - Stati Uniti d'America 23.468
GB - Regno Unito 4.545
IT - Italia 3.799
DE - Germania 2.151
SE - Svezia 1.552
CN - Cina 1.097
FR - Francia 654
UA - Ucraina 601
HK - Hong Kong 489
FI - Finlandia 390
TR - Turchia 353
PL - Polonia 270
BG - Bulgaria 262
IN - India 142
BE - Belgio 129
RU - Federazione Russa 94
IE - Irlanda 92
CA - Canada 84
SG - Singapore 73
CH - Svizzera 57
VN - Vietnam 57
LT - Lituania 50
JP - Giappone 47
NL - Olanda 46
IR - Iran 35
BR - Brasile 34
ES - Italia 34
MY - Malesia 34
KR - Corea 31
RO - Romania 23
EU - Europa 21
ZA - Sudafrica 20
PT - Portogallo 18
AU - Australia 14
CL - Cile 14
AR - Argentina 12
TW - Taiwan 12
DK - Danimarca 8
GR - Grecia 8
PH - Filippine 8
PK - Pakistan 8
MD - Moldavia 7
NZ - Nuova Zelanda 7
AT - Austria 6
ID - Indonesia 6
IL - Israele 6
RS - Serbia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
EG - Egitto 5
JO - Giordania 5
EC - Ecuador 4
HU - Ungheria 4
TZ - Tanzania 4
BD - Bangladesh 3
MX - Messico 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BY - Bielorussia 2
CO - Colombia 2
DZ - Algeria 2
EE - Estonia 2
IQ - Iraq 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
TH - Thailandia 2
BZ - Belize 1
ET - Etiopia 1
GH - Ghana 1
GL - Groenlandia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
SI - Slovenia 1
TN - Tunisia 1
Totale 40.956
Città #
Southend 3.800
Fairfield 2.982
Houston 2.330
Woodbridge 2.114
Chandler 2.090
Ashburn 1.817
Ann Arbor 1.257
Jacksonville 1.238
Frankfurt am Main 1.181
Seattle 1.145
Dearborn 1.142
Cambridge 1.112
Wilmington 1.047
Nyköping 1.012
Modena 768
Hong Kong 476
Beijing 363
New York 335
Princeton 289
San Diego 271
Sofia 261
Kraków 255
Eugene 229
Helsinki 204
Izmir 194
Fremont 175
Shanghai 175
Redwood City 154
Milan 132
Des Moines 126
Bremen 123
Brussels 100
Bologna 98
London 86
Dublin 82
Rome 77
Parma 75
Falls Church 67
Grafing 58
Boardman 56
Dong Ket 52
Hefei 50
Verona 49
Norwalk 45
San Mateo 45
Ottawa 42
Milwaukee 40
Nanjing 40
Guangzhou 34
Reggio Emilia 34
Kunming 33
Turin 33
Naples 32
Padova 31
Perugia 30
Napoli 29
Jinan 27
Phoenix 27
Washington 27
Paris 26
Ferrara 25
Piacenza 23
Saint Petersburg 23
Sassuolo 22
Toronto 22
Auburn Hills 21
Los Angeles 21
Formigine 20
Prato 20
Kilburn 19
Torino 19
Leawood 18
Albinea 17
Trieste 17
Amsterdam 16
Augusta 16
Bari 16
Brescia 16
Hangzhou 16
Singapore 16
Berlin 15
Florence 15
Indiana 15
Leuven 15
Misterbianco 15
Philadelphia 15
Siena 15
Mountain View 14
San Gimignano 14
Catania 13
Chengdu 13
Decatur 13
Dongguan 13
Segrate 13
Cape Town 12
Pavia 12
Salerno 12
Vicenza 12
Ardabil 11
Bomporto 11
Totale 30.873
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.034
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 570
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 419
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 322
Metodo per la funzionalizzazione sito specifica di molecole proteiche 316
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 311
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 292
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 290
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 284
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 275
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 265
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 259
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 253
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 248
Repurposing of drugs targeting yap-tead functions 242
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 242
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 241
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 236
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 235
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 231
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 230
Current and Future Chemotherapy for Chagas Disease 229
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 226
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 226
Antibacterial agent discovery using thymidylate synthase biolibrary screening 226
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 225
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. 223
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 221
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 221
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 220
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 220
Translational repression of thymidylate synthase by targeting its mRNA 218
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 218
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 213
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 213
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 212
Crystal Structure of histidine-tagged human thymidylate synthase 212
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 211
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 209
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 208
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 208
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 207
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 207
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 205
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 205
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 205
Thymidylate synthase inhibition: A structure-based rationale for drug design 201
Thymidylate synthase structure, function and implication in drug discovery 200
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 200
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 200
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 200
Structure-based studies on species-specific inhibition of thymidylate synthase 198
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 197
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 195
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 195
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 195
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 195
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 195
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 193
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 193
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescenceresonance energy transfer. 192
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. 192
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 192
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 190
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 190
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 190
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 188
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 186
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 186
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 184
MITO-group Multicenter italian trials in ovarian cancer and gynecological malignancies Borad of directors-translational research group 184
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 182
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 181
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 180
Update on antifolate drugs targets 180
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 180
Theoretical study of electronic spectra and photophysics of uracil derivatives. 180
Homodimeric Enzymes as Drug Targets 179
Tethering low affinity ligands to the dimeric interface of human thymidylate synthase. 179
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 179
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 179
Biochemical effects of riluzole on Leishmania parasites 178
Optimization of N-alkylation in the Synthesis of Methotrexate and Pteridine-based Derivatives Under Microwave-Irradiation 176
Protein-protein interaction inhibitors: case studies on Small Molecules and Natural Compounds. 175
Biochemistry: Anchors away 175
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 174
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine 173
Inhibitor of Ovarian Cancer Cells growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase 173
Ligand-Based Virtual Screening and ADME-Tox Guided Approach to Identify Triazolo-quinoxalines as Folate Cycle Inhibitors. 172
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development 171
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 171
Naphthalimido Derivatives as Antifolate Thymidylate Synthase Inhibitors 168
Allosteric Inhibition of human Thymidylate Synthase. 168
ANTICANCER DRUGS 167
Structure-Based Optimization of a Non-β-lactam Lead Results in Inhibitors That Do Not Up-Regulate β-Lactamase Expression in Cell Culture 166
QUINOXALINE DERIVATIVES AS ANTITUBERCULOSIS AGENTS 166
Chairperson EUTROC- Mayo Conference-Berlin - Preliminary characterization of pharmacodynamic biomarkers for LR-peptide growth inhibition of ovarian cancer (OC) cell models. 164
ACS Medicinal Chemistry Letters. member of the Editorial Board 163
A proteomic approach to investigate the mechanism of action of anticancer peptides 163
pH sensitive PEGylated Liposomes delivering active hydrophilic peptide with anticancer activity: in vitro study on cDDP-resistant ovarian cell line 162
Totale 22.038
Categoria #
all - tutte 147.433
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.433


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.911 0 0 0 0 0 0 0 0 0 0 1.155 756
2019/20208.638 645 279 346 873 1.102 1.125 1.359 918 743 306 473 469
2020/20217.774 750 311 736 642 848 621 558 770 381 1.171 571 415
2021/20225.532 246 536 330 303 243 554 249 356 626 393 1.058 638
2022/20236.329 759 759 421 608 644 897 190 604 753 103 308 283
2023/20244.983 202 278 326 412 1.996 486 280 492 138 133 240 0
Totale 41.644